ABSTRACT A total of 1533 patients received primary aortic and/or mitral valve replacement, with or without tricuspid valve surgery or other associated cardiac procedures, from January 1, 1975, to July 1, 1979. Actuarial survival at 5 years was 74%. The hazard function (instantaneous risk) of death was highest immediately after operation. Among the incremental risk factors for premature death from any cause were preoperative NYHA class, any valve lesion other than aortic stenosis, aortic cross-clamp time, and combined aortic and mitral valve replacement. Ten modes of death were identified, each with its unique hazard function and risk factors. The commonest mode was cardiac failure. Sudden death was the next commonest, and the early phase of its hazard function peaked about 3 weeks after operation. Seventy-five patients (6.7% of the 1533) had 103 valve reoperations in the follow-up period. Actuarial survival after reoperation was less than that after the primary operation; whether the reoperation was the first, second, or third was a risk factor. Actuarial freedom from prosthetic valve endocarditis (PVE) was 97% at 1 year, and that of periprosthetic leakage without evident infection was 98.8%; the hazard function for the event PVE had an early phase peaking at about 6 weeks and a constant low phase throughout, whereas that of periprosthetic leakage had a single early peaking phase. After reoperations, the actuarial freedom from PVE and periprosthetic leakage was less than that after the original operation. The risk factors for the development of periprosthetic leakage without evident infection were similar but not identical to those for PVE. Among patients receiving a bioprosthesis, 91 % were free of bioprosthetic degeneration 5 years after operation. The hazard function was single and continuously rising, and young age and female gender were risk factors. Actuarial freedom from acute prosthetic thrombosis was 97.9% at 5 years. The single hazard function for this event peaked at 10 months. The risk of thrombosis was higher in female patients. The uses of this integrated study, and the inferences from it, are described. Circulation 72, No. 4, 753-767, 1985 
THE REPLACEMENT of diseased cardiac valves is an accepted form of treatment for many patients with valvular heart disease. The in-hospital mortality for most of these operations is now low but does not approach zero, and premature death and other unfavorable events continue to complicate the subsequent course of patients undergoing them. In-hospital and later death, as well as other events, have usually been addressed separately and as isolated complications, and the nature of their time-relatedness has been assumed.
We performed an integrated study of most of the time-related events that occur after valve replacement, coronary artery bypass grafting (n = 412 patients), resection of left ventricular aneurysm (n -13), resection of ascending aortic aneurysm (n -82), tricuspid annuloplasty (n = 73), tricuspid replacement (n = 6), resection of subaortic stenosis (n -13), repair of atrial septal defect (n = 6), and others (n = 6). Median age of the 1533 patients was 57 years (range 8 to 85 years); 70% were between 41 and 69 years of age and 95% were between 22 and 76 years.
The time-related events studied were death (considered to be premature in the context of a 5 year follow-up and an observed median survival of 8.6 years for male persons and 11 .2 years for female persons aged 75 to 80 years in the 1976 U. S. Life Table) , mode of death, reoperation on the valve originally replaced, and the valve complications of prosthetic valve endocarditis (PVE), periprosthetic leakage without evidence of PVE, bioprosthetic degeneration, and acute prosthetic thrombosis.
Information concerning early, in-hospital events was obtained from review of individual hospital charts and that concerning events occurring after hospital dismissal was obtained from personal evaluation of the patient at return visits and from replies to letters sent to the patients and their physicians. If The operations were done with simple hypothermic ischemic cardiac arrest until 1977 and with cold cardioplegic cardiac arrest thereafter.' The Bjork-Shiley valve was the most commonly used mechanical prosthesis, with three patients receiving a Starr-Edwards prosthesis in the mitral position and two in the aortic position and one patient receiving a Lillehei-Kaster prosthesis in the aortic position. Both the Hancock (n = 241) and Carpentier-Edwards (n = 235) bioprostheses (porcine heterografts) were used; in addition, three patients received a porcine heterograft of unspecified type, and one patient received an aortic homograft for aortic valve replacement. Interrupted simple sutures of Dacron were most frequently used in suturing the prosthetic device in place, but interrupted pledgetted mattress sutures and, in the mitral position, continuous polypropylene sutures were used in many patients. Patients receiving Bjork- Shiley or other mechanical prostheses systematically received warfarin, beginning 48 hr after operation and to continue throughout life. Patients receiving bioprostheses usually were not given warfarin, even early after surgery. Prophylactic antibiotic treatment was given for 4 to 6 days early after surgery and was advised for later dental extractions, operations, and injuries but the details of compliance are not known. In most reoperations, the original prosthetic device was replaced. Repair rather than re-replacement was done in one of the 42 operations for PVE and in 12 of the 37 for periprosthetic leakage without evident infection; thrombectomy rather than replacement was done in three of the 11 reoperations for acute thrombosis.
Among the 1533 patients, 67 (4.4%) died in the hospital after the operation; 271 patients (17.7%) died later. Also, 75 patients (4.9%) underwent 103 reoperations on the valves that had been replaced. Fifty-eight patients (3.8%) developed 65 episodes of PVE, and 31 (2.0%) developed 39 episodes of periprosthetic leakage without evident infection. Thirteen (2.9% of 446 patients receiving a bioprosthesis) developed bioprosthetic degeneration, and 19 (1.8% of the 1084 patients receiving a BjorkShiley prosthesis) developed acute thrombotic occlusion (one patient with a bioprosthesis developed this complication).
No attempt was made to separate the events into those occurring in-hospital (or within 30 days of operation) and those occurring later because of the artificiality imposed by such a strategy. Instead, all events were dated to the conclusion of cardiopulmonary bypass (no deaths occurred between the time patients were taken to the operating room and the start of cardiopulmonary bypass), which for convenience is referred to as the time of operation. The identification and classification of events, including modes of death, were done by the investigators after repeated detailed review of in-hospital and follow-up documents, some from hospitals elsewhere, and after personal telephone calls to patients, their families, and their physicians.
The mode of death (the category, syndrome, or pattern describing the subsystem failure or event that appeared to be associated with the death) was determined for each of the 298 patients who died after the original operation without reoperation; the 40 patients dying after reoperation were not included. Ten categories emerged: death with cardiac failure (acute, subacute, or chronic), sudden death (defined according to the Framingham study criteria of unexpected death without evidence of arrhythmia, occurring within an hour of the onset of symptoms2), arrhythmic death (deaths, usually sudden, with documented life-threatening ventricular arrhythmias in close proximity to the death), death with documented uncontrolled and symptomatic infection (mediastinitis. blood stream or prosthetic infection), other cardiac deaths (delayed cardiac tamponade, death after a subsequent unrelated cardiac operation), death with postoperative hemorrhage, neurologic death, death with cancer, death with trauma, and death with other specific but miscellaneous modes (hepatitis, late acute or subacute pulmonary insufficiency, long-term drug and/or alcohol abuse, chronic renal failure, cirrhosis of the liver, diverticulitis with complications, systemic lupus erythematosus, massive hemoptysis of undetermined etiology, and after unrelated noncardiac surgery).
There were no more than four patients in any one category of the miscellaneous modes. Assignment of mode of death was made independently by the two authors and was virtually self-evident and agreed upon in 271 patients. In 27 patients, the mode of death was either not agreed upon or undiscernible, and therefore no mode was assigned.
Reoperations refer to any subsequent operation on a prosthetic valve inserted at the original operation. Ten The details of the method, the equations, and the shaping parameter estimates and risk factor coefficients for the hazard functions of each event are contained in appendixes 1 and 2. These may be used to recalculate the various nomograms and may be compared with estimates made from a different data set.
The hazard function is expressed as incidence of the event per CIRCULATION 754 month (an arbitrarily selected unit of time). The hazard function analysis determines whether or not the risk is a constant one with time or whether it is in one or several phases. When there is more than one phase in the hazard function, the hazard function(s) that change(s) with time is (are) added to any constant hazard function that is present. Thus, when an early declining phase of increased risk and a constant phase are both present, the hazard function during the postoperative interval in which the early phase is present is the sum of both the early and constant hazard functions. The 70% confidence limits around the hazard function are presented to facilitate estimating the likelihood that differences are not due to chance. For some analyses. the parametric survivorship function has been used to calculate the probability of an event occurring within any time period. The survival and hazard functions are presented along with those of an age-race-sex-matched U. reoperation. Actuarial survival after the third reoperation (n = 8, four deaths) was 75% (CL 57% to 87%) at 24 hr after surgery, the same at 2 weeks, 56% (CL 36% to 74%) at 1 year, and 38% at 2 years (CL 20% to 60%); after the fourth reoperation (n = 2), one of the patients died 1 hr after surgery and the other died 10 months later.
and the procedure used at reoperation (replacement vs repair). For events other than death following a given operation, the patient was censored at the time of another operation, if one occurred. In the case of the event death, no censoring was done at the time of any reoperation except in the analyses of modes of death.
Results
Premature death Original valve replacement operation. Actuarial survival after the original valve replacement operation was 98.5% at 24 hr (CL 98.2% to 98.8%), 96.3% at 2 weeks (CL 95.8% to 96.8%), 87.3% at 1 year (CL 86.4% to 88.1%), and 73.6% at 5 years (CL 72.2% to 75.0%) (figure 1). The hazard function or instantaneous risk of death was highest immediately after operation, fell rapidly during the first postoperative month, and became a constant lower hazard phase by about 3 months after operation (figure 2).
Older age was an incremental risk factor for premature death in both the early phase (p = .01) and the constant phase (p = .02); the age effect is not very strong, however, since 5 Mlonths after Operation AObtained by solution of the multivariate equation (see appendixes 1 and 2) for death in all modes. In solving for the predicted survivals for the individual valve lesions, NYHA functional class was set at III, age at 60 years, 15% of the patients black, and the aortic cross-clamp time (with cardioplegia) 60 min. Actuarial survival for the total group (n = 1533) for 5 years was 73.6% (CL 72.2% to 75.0%). ll more rapidly, essentially to disappear at about 2 weeks; the hazard function after this was a constant phase that was higher than that after primary valve replacement (figure 2).
There were fewer incremental risk factors for premature death after valve reoperations than after the original valve replacement operation. No demographic variables appeared. The number of the reoperation was a risk factor, the risk of death in the early phase increasing with each subequent reoperation (p = .04). Among the valve lesions, only mitral valve disease (stenosis and/or incompetence) increased the risk, and that was in the constant phase (p = .0005). Higher NYHA functional class was a risk factor in the early phase (p = .04). Among the surgical variables, only use of a mechanical prosthesis (rather than a bioprosthesis or repair) was a risk factor, and then in the constant phase (p = .04).
According to the time-related risk factor analysis (see appendix 2), for a patient in NYHA class I the predicted 2 week survival after the original operation TABLE 2 and that after the first reoperation are 99.7% (CL 99.6% to 99.8%) and 98.9% (CL 97.9% to 99.4%), respectively, and those for 5 years are 82% (CL 81% to 84%) and 46% (CL 35% to 58%), respectively. With more advanced preoperative disability and/or repeated reoperations, both early and late predicted survival are lower (table 2) .
Modes of death. Ten modes of death after the original valve replacement operation were identified (table 3) . The hazard functions for the various modes were highly variable ( figure 3) .
Cardiac failure. AIn 27 additional patients a mode of death could not be agreed upon; their hazard function is depicted as K in figure 3 . Seventy-five patients had reoperations, of whom 40 died after the first or subsequent operations and are not included in this analysis.
BSymbols used in figure 3.
failure were similar to those for all deaths (table 4) . Longer aortic cross-clamp time and increased preoperative functional disability only slightly increased predicted 2 week mortality after valve replacement for aortic stenosis, but both were associated with an evident increase in risk when the operation was for aortic incompetence, mitral valve disease, and particularly when it was a double valve replacement for aortic incompetence and mitral valve disease (figure 4). Sudden death. Sudden death (62 events) was the next commonest mode of death (see table 3 ). Its hazard function peaked at about 3 weeks after operation and fell to become constant by about 8 months after surgery (see figure 3) . The risk factors for sudden death included three variables (aortic incompetence, mitral valve stenosis and/or incompetence, and NYHA func- See table 3 for meaning of symbols.) An age-sex-race-matched general population has an incidence of deaths/month of 0.001 across a 5 year period. Neurologic. The hazard function for neurologic death (27 events) was constant and low across the time of this study (see figure 3) . Older age at operation (p = .008) was the only risk factor. Autopsy was performed in four of the 27 patients and in all four there was evident intracranial disease (cerebral embolus in one, cerebral thrombosis in the bulbar area in one, multiple areas of cerebral hemorrhage in one, and diffuse brain necrosis in one. In addition, seven other patients with a neurologic mode of death had evidence of intracranial hemorrhage at the time of intracranial surgery or study by computed tomography.
Other modes of death. The hazard function for death with cancer was constant across time (see figure 3) ; only older age at operation (p = .07) was a risk factor. The hazard function of death with hemorrhage had a single phase and was highest immediately after operation and declined rapidly to essentially disappear after Although reoperation was not considered as a possible risk factor for death after the original operation, its occurrence in a patient increased the subsequent risk of death (see figure 1 ). If considered an additional "mode of death," it would be the third most common (table 3) . PVE. The actuarial freedom from PVE after the original valve replacement operation was 97.0% (CL 96.5% to 97.4%) at 1 year and 95.6% (CL 95.0% to 96.2%) at 5 years after the original operation; it was lower after reoperations (figure 7 ). The hazard function for PVE peaked at 6 weeks after the original operation and then declined to a lower constant hazard function by about 6 months after surgery (figure 8 figure 9 ). The single phase hazard function for leakage after the original valve replacement operation peaked at about 2 months after operation and steadily declined thereafter; that after the re-replacement operations was high initially and declined slowly (figure 10). The incremental risk factors for periprosthetic leakage without evident infection after the original valve replacement (table 7) resembled but were not the same as those for PVE (see figures 9 and 10) . Also, the hazard function for periprosthetic leakage without evident infection was constant with time after reoperation for periprosthetic leakage, whereas it had a peak at 3 months after reoperation for PVE ( figure 1 1 ,A) both peaked at about 6 weeks after surgery and gradually declined toward zero thereafter ( figure 1 1, B) . Bioprosthetic degeneration. Actuarial freedom from bioprosthetic degeneration in patients receiving a porcine heterograft fell to 91% (CL 88% to 93%) by 5 years. The hazard function had a single rising phase (figure 12). Young age at the time of insertion of the bioprosthesis (p < .0001) and female gender (p = .02) were the risk factors for bioprosthetic degeneration. The predicted probability of important bioprosthetic degeneration within 5 years in persons aged 30 years at the time of insertion is 23% for women and 6% for men ( figure 13) .
Acute prosthetic thrombosis. Actuarial freedom from thrombosis after the original valve replacement was 97.9% (CL 97.4% to 98.4%) at 36 months among patients receiving the Bjork-Shiley prosthesis. The hazard function for acute thrombosis of Bjork-Shiley prostheses peaked at 10 months and declined nearly to zero by 6 years ( figure 14) . The single risk factor was female gender (p = .0006). There was no recurrence of the acute thrombosis in the three patients in whom simple thrombectomy, rather than valve replacement, was done. dence of premature death in patients who have undergone valve replacement. The variability of the autopsy findings within one mode of death, however, indicates the need for caution in using this information. The relative frequency with which events, including death, occur in the first few months after hospital dismissal makes it evident that the artificiality of emphasizing in-hospital deaths underestimates the incidence of early events. This has been avoided in this study by the use of a method that identifies differing risks across time by decomposing them into hazard phases, with their unique incremental risk factors.
Two important events have not been addressed by this study. One is thromboembolism and the other warfarin-related hemorrhage. There is a considerable degree of uncertainty in attributing death to either of these, but no doubt they have been the causes of some sudden and neurologic deaths.
A limitation of this study is that no prophylactic valve reoperations have been performed in these patients. In all likelihood, there is an overall lower incidence of death and other time-related untoward events after prophylactic valve reoperations than after those done for the indications present in this group of patients. However, the multivariate equation derived from the data in this study (see appendixes 1 and 2) can be used to estimate the probability of death (and other time-related events) in a specific patient after a valve reoperation done prophylactically and in anticipation of failure of a prosthetic valve. The NYHA functional class can be set for that patient, and in the case of most prophylactic operations is I or II. The aortic crossclamp time can be predicted with reasonable certainty by the surgeon. The other variables in the multivariate equation can also be set specifically for the patient at hand. Thereby the predicted 2 week or 5 year survival can be determined for the patient (as was done in table 2), and these can be compared with those of no reoperation.
The early and late survival probabilities of individual patients being considered for an original valve operation can also be estimated from the multivariate equations in a similar manner. These can be compared with the probability of survival with nonsurgical treatment, as an aid in making the decision about valve replacement.
The data and methodology can also be used to make valid comparisons with experiences in a different era in the same institution or in different institutions, a process that otherwise can be difficult because of potential differences in the age, functional status, and valve lesions of the patients (see appendix 3). Such comparisons can be useful in assessing progress, evaluating the quality of programs, and identifying means of improving results.
Premature death and its modes. The overall 5 year actuarial survival of about 75% is similar to that in previous reports.9`'3 The inadequacy of using hospital survival figures as criteria of the early risks and result of a valve replacement operation is evident from the fact that the early phase of higher risk does not end with hospital dismissal or on postoperative day 30, but rather does not merge with a constant risk phase until about 3 months after operation.
It may be inferred from the data that improvement in survival after valve replacement operations could be achieved by reducing the incidence of deaths with cardiac failure and those that occur suddenly. The risk factors for these two most common modes of death suggest that they are associated with preoperatively important left ventricular secondary cardiomyopathy and dysfunction. The deaths in these modes that occur in the very early days after operation might be reduced figure 2) . Favorably influencing the risk factors for the indications for reoperation (PVE, periprosthetic leakage without evident infection, valve thrombosis, and bioprosthetic degeneration) would reduce the overall risk of premature death after valve replacement. PVE, usually with periprosthetic leakage, is often difficult to distinguish from periprosthetic leakage through evident infection. The similarities between the risk factors for PVE and those for periprosthetic leakage without evident infection, and the similarities between the hazard functions of these two events, suggest that some of the latter may in fact be instances of PVE. A precise surgical technique, scrupulous attention to the details of asepsis, and effective antibiotic prophylaxis are important in improving the overall results of primary valve replacement operations. Furthermore, the hairy chests of men may result in the presence of more skin bacteria at the time of operation than in women, and the reduction of the strength of male gender as a risk factor for these events may require improved methods of skin preparation for operation. The use of bioprostheses, including cryopreserved homografts in the aortic position, whenever there is native valve endocarditis or PVE could be expected to minimize these complications and thus the need for reoperation. 3' 15 Because the increase in risk of premature death after valve replacement that is associated with older age is small, patients should not be advised against operation just because they are elderly. Neither should operation be advised prematurely, on the basis of advancing years. The association of black race with an increased hazard of premature death in the early phase of a number of modes may be related to the higher incidence of hypertension and left ventricular hypertrophy in blacks.
The study does not provide support for the preference of bioprostheses over mechanical valves, or vice versa, except when the operation is being done for native valve endocarditis (see above). Although bioprosthetic degeneration, a slow process in older male patients (see figure 13) , may require reoperation, the risk of this is low when done while the patient's functional status is good (see table 2 ). The relative rapidity of bioprosthetic degeneration in persons less than about 45 years old, and especially in women, cautions against the use of bioprostheses in such individuals.
Reoperation. There is a tendency to consider valve reoperation after an original valve replacement operation as a benign event, but this is not supported by this study. An increasing risk of complications after multiple valve reoperations has also been reported by Sandza et al. '7 This and the increased risks of death, reoperation, PVE, and periprosthetic leakage without evident infection after valve reoperations make it apparent that every effort should be made to make the first operation a lasting one.
PVE. Although PVE occurs uncommonly after an original valve replacement operation, it is a serious complication with a mortality of 63% in the patients in this series3 and a similar mortality in the experience of others. '8 19 Its early peaking hazard phase is probably caused by organisms present in the patient's valve area or introduced there at the time of operation, whereas its constant phase is probably related to transient bacteremias during which organisms lodge in the valve area.3 It is likely that the contention of Miller et al. 18 that the hazard of this event across time is constant resulted from their failure to decompose in detail the early period after operation.
Periprosthetic leakage without evident infection. In view of the data in this study, when the leakage is mild, nothing should be done surgically because the reoperation in this setting carries the same risks of untoward postoperative events as do other reoperations. When reoperation is indicated and there is no suggestion that PVE is present, the data support the use of repair of the leakage whenever possible, rather than rereplacement.
Bioprosthetic degeneration. (9) that is, a linear regression model. Equation 8 is the logistic equation, expressed in cumulative hazard. The parametric scaling function for the constant and increasing hazard phases are log-linear (proportional hazards) regression models: /1.2 -exp (p3 x 2) (10) and /3 exp(/3 X3) (11) All parameters and regression coefficients were estimated simultaneously by the method of maximum likelihood. Structural parsimony of the model was determined by the likelihood ratio test. Asymptotic p values for regression coefficients were based on the ratio of each coefficient to its standard deviation, and confidence limits for estimated functions were determined by the method of statistical differentials.
Appendix 2
Parameter estimates and regression coefficients For each event analyzed, shaping parameter estimates and intercepts are given for the parametric estimates of events across time (hazard function and survivorship function); these plus regression coefficients are given from the multivariate analysis 766 of the event. These are organized according to their time of influence on the hazard function: throughout and constant, early and decreasing, and late and increasing. For dichotomous variables, the presence of the stated factor takes on the value of 1, its absence 0; thus its coefficient is used when the factor is present and not used when it is absent. In the text, an average value for a dichotomous variable is used occasionally; in this case, that value is multiplied by the listed coefficient. For continuous variables, the units of the variable are multiplied by the coefficient in the equation.
